在BRAF突变NSCLC中应对治疗挑战:非V600突变,免疫疗法和克服抗性
Martina Bortolot1,2, Sara Torresan1,2, Elisa De Carlo1
1Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy.
International journal of molecular sciences
|December 17, 2024
概括
在非小细胞肺癌 (NSCLC) 中的BRAF突变带来了治疗挑战. 本综述涵盖了目前的疗法,免疫疗法潜力和BRAF突变NSCLC的耐药性机制.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 药理学 药理学是指药理学的学科.
背景情况:
- BRAF突变很少见,但在非小细胞肺癌 (NSCLC) 中具有治疗挑战性.
- 针对BRAF V600E突变存在向疗法,但对于II和III类突变不存在,从而造成治疗不确定性.
- 免疫疗法在BRAF突变的NSCLC中显示出潜在的有效性,特别是在吸烟者中,尽管对其他基因组变异的益处有限.
研究的目的:
- 探索BRAF突变NSCLC中的关键管理挑战.
- 提供关于BRAF突变NSCLC治疗的当前证据的全面摘要.
- 突出正在进行的临床试验,解决治疗缺口和耐药性机制.
主要方法:
- 对BRAF突变NSCLC目前证据的文献综述.
- 对治疗策略的分析,包括向抑制剂和免疫治疗.
- 检查对BRAF途径抑制剂的耐药性机制.
主要成果:
- BRAF/MEK 抑制剂组合可以改善 V600E 突变的存活率.
- 对于II/III类BRAF突变,目前还没有针对性的治疗方法.
- 免疫疗法在BRAF突变的NSCLC中表现出类似的疗效,特别是在吸烟者中.
结论:
- 与BRAF突变的NSCLC需要超越当前抑制剂的新型治疗策略.
- 对BRAF抑制剂的耐药性是不可避免的,需要研究克服这些机制.
- 进一步的临床试验对于解决未满足的需求和改善BRAF突变NSCLC患者的治疗结果至关重要.
更多相关视频
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
10.5K
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
8.8K
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Tumor Immunotherapy
475
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
475
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Cancer Vaccines
338
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
338
